Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-1: Loncastuximab tesirine in R/R B-NHL
NCT02669017Phase 1Completed
- Sponsor
- ADC Therapeutics
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of loncastuximab tesirine in B-cell non-Hodgkin lymphoma (2 arms), sponsored by ADC Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Recommended Dose of ADCT-402 for Part 2 and 2 more. Started Mar 2016; status: completed.
02
Drugs
loncastuximab tesirine
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02669017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669017.